---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000066"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T10:20:50.436153+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xeris Q1 revenue $33.2M (+50% YoY); reaffirms 2023 guidance

## Summary
- Total revenue $33.2M vs $22.1M in Q1 2022; Gvoke net revenue $15.0M (+21%), Keveyis $12.8M (+37%), Recorlev $4.5M.
- Net loss $16.8M ($0.12 per share); cash & investments $95.1M at March 31, 2023.
- 2023 guidance: revenue $135M-$165M; cash from ops ($57M)-($77M); year-end cash $45M-$65M.
- Announced XeriJect collaboration with Regeneron for two undisclosed monoclonal antibodies.
- Appointed Ricki Fairley to Board of Directors, increasing board to nine members.

## SEC filing metadata
- accession: 0001867096-23-000066
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000066/0001867096-23-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000066/xers-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000066
- JSON: https://secwatch.observer/filing/0001867096-23-000066.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000066.txt

## Key facts
- Earnings Releases
  Xeris Biopharma Holdings, Inc. reported first quarter ended March 31, 2023 results: revenue $33.2M, net income $16.8 million, EPS $0.12 per share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2023
  - Revenue: $33.2M
  - Net income: $16.8 million
  - EPS: $0.12 per share
  - Guidance: reaffirmed
  - Result: reported results
  source text: forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- XERIS BIOPHARMA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Achieved first quarter total revenue of $33.2M representing 50% growth compared to Q1 2022 Ended Q1 2023 with $95.1M in cash, cash equivalents, and short-term investments Affirms 2023 guidance: total revenue of $135M-$165M;
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000066/0001867096-23-000066-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.